Analyst Coverage

Colleen Kusy, CFA

Baird

Melissa Benson, Ph.D.

Barrenjoey

Thomas Wakim

Bell Potter

Madeleine Williams

Canaccord Genuity

Reni Benjamin, Ph. D.

Citizens

Andrew Paine

CLSA

David Stanton, Ph.D.

Jefferies

Jason McCarthy, Ph.D.

Maxim Group

Boris Peaker, Ph.D., CFA

Titan Partners

Analyst Reports

This information is provided for information purposes only. The opinions, estimates, forecasts or any analysis do not represent the opinions, forecasts, or any analysis of our Company or management or staff. We do not by its reference imply any concurrence with the independently provided opinions, estimates or forecasts.

Feb 26, 2026

Citizens – F1H26 Update: Upcoming Interim Analysis Remains Key Value Driver Near Term (Analyst: Reni J. Benjamin, PhD)

For a copy of this research report please contact your advisor at Citizens

Feb 25, 2026

CLSA – On track for a big year; Outperform, A$0.95 PT (Analyst: Andrew Paine)

For a copy of this research report please contact your advisor at CLSA

Feb 24, 2026

Jefferies – 1HFY26 – No Time for Games; BUY, PT A$2.20 (from A$2.30) (Analyst: Dr David Stanton)

For a copy of this research report please contact your advisor at Jefferies

Feb 23, 2026

Citizens – CORRECTION: “TACTI-Fully” Expanding the Checkpoint Market; Initiating with Market Outperform, US$10 PT (Analyst: Reni J. Benjamin, Ph.D.)

For a copy of this research report please contact your advisor at Citizens

Feb 17, 2026

Citizens – “TACTI-Fully” Expanding the Checkpoint Market; Initiating with Market Outperform, US$6 PT (Analyst: Reni J. Benjamin, Ph.D.)

For a copy of this research report please contact your advisor at Citizens

Jan 30, 2026

Titan Partners – 2H FY2025 Update, Key Milestones Reconfirmed; Rated Buy, USD $5.50 PT (Analyst: Boris Peaker, Ph.D. CFA)

For a copy of this research report please contact your advisor at Titan Partners

Jan 30, 2026

Bell Potter – Q2 update – Phase 3 rapidly advancing, futility analysis imminent. Maintain BUY (spec.); increase valuation to A$0.65/sh (prev. $0.60); (Analyst: Thomas Wakim)

For a copy of this research report please contact your advisor at Bell Potter

Jan 29, 2026

Baird – F2Q26: Nearing Futility Analysis for Pivotal 1L NSCLC Study in 1Q26; Maintain OP rating, US$7.00 PT (Analyst: Colleen M. Kusy, CFA)

For a copy of this research report please contact your advisor at Baird

Dec 22, 2025

Barrenjoey – Positive IMP761 Phase I Update; Rated Overweight, A$1.50 PT (Analyst: Dr Melissa Benson)

For a copy of this research report please contact your Barrenjoey advisor

Dec 22, 2025

Titan Partners – IMP761 Update in Autoimmune Diseases; Rated Buy, US$5.50 PT (Analyst: Boris Peaker, Ph.D. CFA)

For a copy of this research report please contact your advisor at Titan Partners

Dec 16, 2025

Barrenjoey – Ready for an IMM-pact; Initiating with Overweight, A$1.50 PT (Analyst: Dr Melissa Benson)

For a copy of this research report please contact your Barrenjoey advisor

Dec 15, 2025

Titan Partners – A TACTI-cal Shift: From Lagging to Leading in Immuno-Oncology; Initiating with Buy, US$5.50 PT (Analyst: Boris Peaker, Ph.D. CFA)

For a copy of this research report please contact your advisor at Titan Partners